The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 18 of the 49 sources its claims cite were checked for support.
Design of protein-binding proteins from the target structure alone
Open accessAbstract
The design of proteins that bind to a specific site on the surface of a target protein using no information other than the three-dimensional structure of the target remains a challenge 1–5 . Here we describe a general solution to this problem that starts with a broad exploration of the vast space of possible binding modes to a selected region of a protein surface, and then intensifies the search in the vicinity of the most promising binding modes. We demonstrate the broad applicability of this approach through the de novo design of binding proteins to 12 diverse protein targets with different shapes and surface properties. Biophysical characterization shows that the binders, which are all smaller than 65 amino acids, are hyperstable and, following experimental optimization, bind their targets with nanomolar to picomolar affinities. We succeeded in solving crystal structures of five of the binder–target complexes, and all five closely match the corresponding computational design models. Experimental data on nearly half a million computational designs and hundreds of thousands of point mutants provide detailed feedback on the strengths and limitations of the method and of our current understanding of protein–protein interactions, and should guide improvements of both. Our approach enables the targeted design of binders to sites of interest on a wide variety of proteins for therapeutic and diagnostic applications.
Overview
CoChat Summary
TL;DR
The paper describes a two-stage computational pipeline that designs small protein binders from the target structure alone, without native complex or hotspot information. It validates the approach across 12 diverse protein targets, yielding optimized binders with 300 pM–900 nM affinities and crystal structures that closely match the design models.
Key findings
- De novo binders were designed to 12 diverse protein targets (13 target sites on 12 native proteins), all smaller than 65 amino acids; optimized affinities ranged from 300 pM to 900 nM (Table 1), with examples including IL-7Rα at 0.31 nM, VirB8 at 0.51 nM, TrkA at 1.4 nM, EGFRn at 1.2 nM, H3 at 320 nM and IGF1R at 860 nM.
- Nine out of 13 designs were stable at 95 °C, and all expressed in the soluble fraction in *E. coli* and had circular dichroism spectra consistent with the design models.
- Crystal structures of five binder–target complexes (H3, TrkA, FGFR2, IL-7Rα and VirB8) closely matched the computational design models; Cα r.m.s.d. values over the entire miniprotein binder were 1.91 Å (H3), 2.41 Å (TrkA), 1.33 Å over the FGFR2 complex, 2.2 Å (IL-7Rα) and 2.54 Å (VirB8). Cryo-EM structures of SARS-CoV-2 binders LCB1 and LCB3 also matched design models with Cα r.m.s.d. values of 1.27 Å and 1.9 Å.
- Analysis of 810,000 binder designs and 240,000 single mutants showed design success varied by target; success correlated strongly with the hydrophobicity of the targeted region, and experimentally binding designs tended to have stronger predicted binding energy and larger contact molecular surfaces.
Methods
- Broad search: billions of disembodied amino acids were docked against selected target surface regions using RifGen/RIF; 84,690 miniprotein scaffolds (50–65 residues, 5 topologies) were encoded, and 34,507 were found stable; scaffolds were docked with PatchDock/RIFDock, followed by Rosetta sequence design and a rapid “Predictor” prescreen.
- Focused search: secondary-structure motifs making good target contacts were extracted and clustered, around 2,000 motifs per target were selected, and scaffolds were grafted onto these motifs for another round of docking and design.
- Experimental validation used yeast surface display with FACS and deep sequencing, site saturation mutagenesis libraries, *E. coli* expression, circular dichroism, biolayer interferometry, X-ray crystallography/cryo-EM, and cell signalling inhibition assays.
Limitations
- Stated in the paper: only a small fraction of designs bind, and in almost all cases the best binders required additional substitutions to achieve high-affinity binding; design of binders to highly polar target sites remains a considerable challenge, as all targeted sites here contained at least four hydrophobic residues.
- Stated in the paper: sampling of the enormous design space is necessarily incomplete, and many broad-search designs contained buried unsatisfied polar atoms and cavities; structures could not yet be solved for the remainder of the designs.
- Evident from the text: the SC50 fitting assumes equal yeast surface expression and 100% expression in the collection gate, assumptions the authors say are “probably false”; expression differences may cause SC50 fits to vary by up to fivefold, and doubly transformed yeast cells are described as a major source of error.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


















Verification
Claims the paper makes
10 Valid · 4 Not valid · 21 Not checked · 118 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Binders have been generated starting from several computationally identified hotspot residues, which were then used to guide the positioning of naturally occurring protein scaffolds5.”
§ Design of protein-binding proteins from the target structure alone > Main
What the sources say
- Supportedcites [5] Fleishman, S. J. et al. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332, 816–821 (2011). source
The Computational design method section (page not provided) describes computationally positioning hotspot residues against the target, then finding scaffold configurations that incorporate them. The Design of HA-binding proteins and Experimental and structural characterization sections confirm that the resulting scaffold-based designs produced HA-binding proteins. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The design of proteins that bind to a specific site on the surface of a target protein using no information other than the three-dimensional structure of the target remains a challenge1–5.”
§ Design of protein-binding proteins from the target structure alone > Abstract
What the sources say
- Partly supportedcites [1] Chevalier, A. et al. Massively parallel de novo protein design for targeted therapeutics. Nature 550, 74–79 (2017). sourceExperimental — accuracy not yet measured
The Abstract and Assessment of the computational model describe limitations in designing protein binders and a low initial success rate, supporting the claim that this remains challenging. But the High-throughput computational design section says the authors used binding motifs and hotspot residues from previously solved complexes, not just the target’s three-dimensional structure. The paper therefore does not establish the claim’s structure-only condition. (LLM, conf=0.83)
- Partly supportedcites [2] Strauch, E. M. et al. Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site. Nat. Biotechnol. 35, 667–671 (2017). sourceExperimental — accuracy not yet measured
The paper describes designing proteins for a specific site on influenza hemagglutinin, but its design used the C05 antibody binding mode and an antibody–target co-crystal structure (design description and Methods > Computational Methods; page not provided). This is consistent with target-structure-only design being difficult, but the paper does not explicitly establish the broader claim that it remains a challenge. (LLM, conf=0.77)
- Partly supportedcites [3] Silva, D. A. et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature 565, 186–191 (2019). sourceExperimental — accuracy not yet measured
The section on computational design of IL-2/IL-15 mimics distinguishes earlier designs for short linear epitopes from its approach to more complex binding interfaces, supporting the general point that designing targeted binders is challenging. But the Methods section says this design used the structure of IL-2 in complex with its receptor as a template; the paper does not establish the specific claim about designing binders with no information beyond the target’s three-dimensional structure. Page numbers are unavailable in our copy. (LLM, conf=0.78)
- Not checked yetcites [4] Baran, D. et al. Principles for computational design of binding antibodies. Proc. Natl Acad. Sci. USA 114, 10900–10905 (2017). source
- Supportedcites [5] Fleishman, S. J. et al. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332, 816–821 (2011). source
The Introduction states that computational design could target specific patches on a protein surface, but that the capability to target an arbitrarily selected surface had remained elusive. This supports the citing sentence’s characterization of the task as a challenge, including the more restricted case where only the target’s three-dimensional structure is available. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Most current computational methods used to design proteins that bind to a target surface utilize information derived from structures of the native complex on specific side-chain interactions or protein backbone placements optimal for binding1–3.”
§ Design of protein-binding proteins from the target structure alone > Main
What the sources say
- Partly supportedcites [1] Chevalier, A. et al. Massively parallel de novo protein design for targeted therapeutics. Nature 550, 74–79 (2017). sourceExperimental — accuracy not yet measured
The High-throughput computational design section describes using interface helices from previously solved target complexes to position scaffold backbones and seed interfaces with hotspot residues. This supports the described design strategy, but the paper does not establish that most current computational methods use it. (LLM, conf=0.83)
- Partly supportedcites [2] Strauch, E. M. et al. Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site. Nat. Biotechnol. 35, 667–671 (2017). sourceExperimental — accuracy not yet measured
The paper’s design description (section labeled Abstract; page unavailable) says it used the C05–HA co-crystal structure to position the target and optimized key interface contacts and backbone alignment. It also compares the approach with earlier antibody-loop grafting. These passages support the described type of structure-guided design, but not the claim that most current protein-binder design methods use it. (LLM, conf=0.82)
- Partly supportedcites [3] Silva, D. A. et al. De novo design of potent and selective mimics of IL-2 and IL-15. Nature 565, 186–191 (2019). sourceExperimental — accuracy not yet measured
The Methods section (page unavailable) says the authors used the structure of the native hIL-2–receptor complex as a design template, identified binding-site residues as hotspots, and built new backbones around its structural elements. This supports the described approach for this method, but the paper does not establish that most current computational methods use such information. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The most robust results were obtained using direct low-resolution shape matching11 followed by grid-based refinement of the rigid body orientation in the RIF (RIFDock).”
§ Design of protein-binding proteins from the target structure alone > Design method
What the sources say
- Partly supportedcites [11] Schneidman-Duhovny, D., Inbar, Y., Nussinov, R. & Wolfson, H. J. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 33, W363–W367 (2005). sourceExperimental — accuracy not yet measured
The PatchDock algorithm section describes matching complementary molecular-surface patches to generate docking orientations, supporting the shape-matching method cited here. It does not describe that matching as low-resolution. The citation is attached to shape matching, not to the sentence’s claims about robust results or subsequent RIFDock refinement. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Neutralizing antibodies that target the stem region of group 2 HA have been identified through screens of large B cell libraries after vaccination or infection that neutralize both group 1 and group 2 influenza A viruses34,35.”
§ Design of protein-binding proteins from the target structure alone > Pathogen target proteins
What the sources say
- Not checked yetcites [34] Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850–856 (2011). source
- Partly supportedcites [35] Joyce, M. G. et al. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell 166, 609–623 (2016). sourceExperimental — accuracy not yet measured
The Introduction and Results report sorting cross-reactive memory B cells after vaccination, then identifying HA-stem-binding antibodies that neutralized both group 1 and group 2 influenza A viruses. The paper describes cell sorting and antibody sequencing, not screening a large B-cell library; the vaccination finding does not establish the infection alternative. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
72 more claims · 1 with their cited sources checked
Create a free account to see all 153 claims and to verify the 31 references still open.
- It may state two separate claims as one. 50
- Probably not a substantial claim. 35
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the approach relied on prespecifying a particular set of protein scaffolds as the basis for the designs, inherently limiting the diversity and shape complementarity of possible solutions12”
From De novo design of protein structure and function with RFdiffusion (2023) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For binder design from target structural information alone, previous work required testing tens of thousands of sequences12.”
From De novo design of protein structure and function with RFdiffusion (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“A general method for de novo binder design from target structure information alone using the physically based Rosetta method was recently described12”
From De novo design of protein structure and function with RFdiffusion (2023) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“However, experimental success rates were low, still requiring many thousands of designs to be screened for each design campaign12”
From De novo design of protein structure and function with RFdiffusion (2023) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Design of protein-binding proteins from the target structure alone > Cell receptors involved in signalling
“the binding affinities of the optimized designs ranged from about 1 nM or better for TrkA and FGFR2 to 860 nM for IGF1R”
§ Design of protein-binding proteins from the target structure alone > Experimental testing
“| Kd (nM) | 320 ± 24.0 | 1.4 ± 0.02 | 243 ± 59.0 | 1.2 ± 0.01 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Design of protein-binding proteins from the target structure alone > Pathogen target proteins
“Similar to FGFR2, IL-7Rα and VirB8, the method yielded picomolar binders”
§ Design of protein-binding proteins from the target structure alone > Experimental testing
“| Kd (nM) | 320 ± 24.0 | 1.4 ± 0.02 | 243 ± 59.0 | 1.2 ± 0.01 |”
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 7,953
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Self-citation
Research works printed but not linked: 1
- Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235–242 (2011).
Cited by
Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahern, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2022) · doi:10.1101/2022.12.09.519842 · Cited by 2,369
Self-citationDe novo design of protein structure and function with RFdiffusion
Watson, J. L., Juergens, D., Bennett, N. R., Trippe, B. L., Yim, J., Eisenach, H. E., Ahern, W., Borst, A. J., Ragotte, R. J., Milles, L. F., et al. (2023) · Nature · doi:10.1038/s41586-023-06415-8 · Cited by 2,325
Self-citationRobust deep learning–based protein sequence design using ProteinMPNN
Dauparas, J., Anishchenko, I., Bennett, N., Bai, H., Ragotte, R. J., Milles, L. F., Wicky, B. I. M., Courbet, A., de Haas, R. J., Bethel, N., et al. (2022) · Science · doi:10.1126/science.add2187 · Cited by 2,210
Self-citationRobust deep learning based protein sequence design using ProteinMPNN
Dauparas, J., Anishchenko, I., Bennett, N., Bai, H., Ragotte, R. J., Milles, L. F., Wicky, B. I. M., Courbet, A., de Haas, R. J., Bethel, N., et al. (2022) · doi:10.1101/2022.06.03.494563 · Cited by 2,107
Self-citationGeneralized biomolecular modeling and design with RoseTTAFold All-Atom
Krishna, R., Wang, J., Ahern, W., Sturmfels, P., Venkatesh, P., Kalvet, I., Lee, G. R., Morey-Burrows, F. S., Anishchenko, I., Humphreys, I. R., et al. (2024) · Science · doi:10.1126/science.adl2528 · Cited by 978
Self-citation
Metadata
- Authors
- Cao, L., Coventry, B., Goreshnik, I., Huang, B., Sheffler, W., Park, J. S., Jude, K. M., Marković, I., Kadam, R. U., Verschueren, K. H. G., Verstraete, K., Walsh, S. T. R., Bennett, N., Phal, A., Yang, A., Kozodoy, L., DeWitt, M., Picton, L., Miller, L., Strauch, E.-M., DeBouver, N. D., Pires, A., Bera, A. K., Halabiya, S., Hammerson, B., Yang, W., Bernard, S., Stewart, L., Wilson, I. A., Ruohola-Baker, H., Schlessinger, J., Lee, S., Savvides, S. N., Garcia, K. C., & Baker, D.
- Affiliations
- University of Washington (US)
- Yale University (US)
- Howard Hughes Medical Institute (US)
- Ghent University (BE)
- Scripps Research Institute (US)
- National Institutes of Health (US)
- University of Georgia (US)
- UCB Pharma (United States) (US)
- Corresponding author
- Baker, David
- ORCID
- Cao, Longxing
- Coventry, Brian
- Goreshnik, Inna
- Huang, Buwei
- Sheffler, William
- Park, Joon Sung
- Jude, Kevin M.
- Marković, Iva
- Kadam, Rameshwar U.
- Verschueren, Koen H. G.
- Verstraete, Kenneth
- Bennett, Nathaniel
- Phal, Ashish
- Yang, Aerin
- Picton, Lora
- Miller, Lauren
- Strauch, Eva-Maria
- DeBouver, Nicholas D.
- Bera, Asim K.
- Yang, Wei
- Bernard, Steffen
- Stewart, Lance
- Wilson, Ian A.
- Ruohola-Baker, Hannele
- Schlessinger, Joseph
- Lee, Sangwon
- Savvides, Savvas N.
- Garcia, K. Christopher
- Baker, David
- Venue
- Nature
- Published
- 2022-03-24
- Volume
- 605
- Issue
- 7910
- Pages
- 551-560
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC9117152
- OpenAlex
- W4220765272
- Cited by
- 577
- References
- 85
- Citations by year
- 2026: 139 · 2025: 176 · 2024: 131 · 2023: 81 · 2022: 48
- FWCI
- 35.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (1s10od012289-01a1, 5r01ai140245-05, 1s10od021527-01)
- Defense Advanced Research Projects Agency
- National Institute on Aging (R01AG063845)
- National Institute of General Medical Sciences (P41GM103393, P30GM138396, P30GM124165)
- National Institute of Allergy and Infectious Diseases (HHSN272201700059C, R01AI150855, R01AI150885, R37AI051321, R01-AI140245)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- de novo protein design, protein-protein interaction, protein surface, nanomolar affinity, point mutants
- MeSH terms
- Amino Acids, Binding Sites, Carrier Proteins, Protein Binding, Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design of protein-binding proteins from the target structure alone. https://app.cochat.ai/papers/10.1038/s41586-022-04654-9
- The paper
- Cao, L., Coventry, B., Goreshnik, I., Huang, B., Sheffler, W., Park, J. S., Jude, K. M., Marković, I., Kadam, R. U., Verschueren, K. H. G., Verstraete, K., Walsh, S. T. R., Bennett, N., Phal, A., Yang, A., Kozodoy, L., DeWitt, M., Picton, L., Miller, L., . . . Baker, D. (2022). Design of protein-binding proteins from the target structure alone. Nature. https://doi.org/10.1038/s41586-022-04654-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.